Legal DealFolio - Novartis acquisition of Genoptix

On January 24, 2011, Novartis and Genoptix, Inc. announced that they have entered into a definitive agreement whereby Novartis will acquire Genoptix in an all-cash offer with a total equity value of US$470 million. Cravath is representing Novartis in this transaction. Under the terms of the agreement, Novartis will commence a tender offer for all outstanding shares of common stock of Genoptix at US$25.00 per share. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close within the first half of 2011. Genoptix, Inc. is a specialized laboratory providing personalized diagnostic services to community-based hematologists and oncologists. The Cravath team included partners Mark I. Greene and Thomas E. Dunn and associates Aaron Gruber, Timothy Y. Shih, Andrew C. Elken, Richard N. Luft, Katherine A. Kohan and Michael Saliba on corporate matters; partner Stephen L. Gordon and associates Joanne Lee and Peter R. Ternes on tax matters; partner Eric W. Hilfers and associate Lori Diamond Goodman on executive compensation and benefits matters; partner Rowan D. Wilson, associate M. Brent Byars and discovery attorney Jonathan J. Clarke on antitrust matters; corporate senior attorney John Gerhard on real estate matters; and practice area attorney Matthew Morreale on environmental matters. Brian J. Cathey also worked on executive compensation and benefits matters.

Deal Date:	24-01-2011	Practice Area:	Corporate and M&A
Deal Title:	Novartis acquisition of Genoptix	Industry:	Pharmaceuticals & Biotechnology
Description:	On January 24, 2011, Novartis and Genoptix, Inc. announced that they have entered into a definitive agreement whereby Novartis will acquire Genoptix in an all-cash offer with a total equity value of US$470 million. Cravath is representing Novartis in this transaction. Under the terms of the agreement, Novartis will commence a tender offer for all outstanding shares of common stock of Genoptix at US$25.00 per share. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close within the first half of 2011. Genoptix, Inc. is a specialized laboratory providing personalized diagnostic services to community-based hematologists and oncologists. The Cravath team included partners Mark I. Greene and Thomas E. Dunn and associates Aaron Gruber, Timothy Y. Shih, Andrew C. Elken, Richard N. Luft, Katherine A. Kohan and Michael Saliba on corporate matters; partner Stephen L. Gordon and associates Joanne Lee and Peter R. Ternes on tax matters; partner Eric W. Hilfers and associate Lori Diamond Goodman on executive compensation and benefits matters; partner Rowan D. Wilson, associate M. Brent Byars and discovery attorney Jonathan J. Clarke on antitrust matters; corporate senior attorney John Gerhard on real estate matters; and practice area attorney Matthew Morreale on environmental matters. Brian J. Cathey also worked on executive compensation and benefits matters.
Financial Center:	New York	Value:	0.00-100.00
Advised Party:	Acquiror	Law Firm	Cravath
Target Company Jurisdiction:	United States	Acquiror Jurisdiction:	United States
Classification:	Strategic Buyer Acquisitions Public Company - Recommended Offer	Lawyer	Mark I Greene

Practice Areas -

Corporate and M&A Law Firms and Lawyers

Practice Areas - Corporate and M&A Law Firms and Lawyers